Merck KGaA Aims To Launch One New Product Or Major Indication Every 1.5 Years On Average

RTTNews | il y a 883
Merck KGaA Aims To Launch One New Product Or Major Indication Every 1.5 Years On Average

(RTTNews) - While providing updates on the company's healthcare research and development strategy, aimed at doubling R&D productivity on Monday, German science and technology firm Merck KGaA (MKGAY.PK) said it will focus its expertise and capabilities and leverage synergies within the existing pipeline to deliver transformative medicines in Oncology, Neurology and Immunology, augmented by an increased focus on external innovation.

This will help it achieve the goal of introducing one new product or major indication every 1.5 years on average. The company expects more than 50% of future launches to result from external co-development partnerships and strategic in-licensing of assets for further in-house development.

The company will also build on its established expertise in the underlying biology of its focused therapeutic areas of oncology, neurology and immunology and will leverage technological capabilities to increase R&D productivity.

The company's oncology research and development strategy centers on cancer DNA while building on existing leadership in key cancer types, including head and neck, urothelial and colorectal cancers.

The lead asset in the oncology pipeline is xevinapant, an investigational first-in-class potent oral small molecule IAP (Inhibitor of Apoptosis Protein) inhibitor being evaluated in the curative setting of locally advanced squamous cell carcinoma of the head and neck.

In neurology and immunology, Merck aims to expand its Multiple Sclerosis (MS) portfolio with evobrutinib, an investigational, oral, CNS-penetrating, highly selective inhibitor of Bruton's tyrosine kinase (BTK) with the potential to become a best-in-class treatment option for relapsing multiple sclerosis (RMS).

Merck also seeks to expand in neurology by evaluating the potential of oral cladribine in neurological diseases where inflammation is a primary driver, such as generalized myasthenia gravis.

Further, the company is looking to diversify the pipeline with immunology and accelerate R&D by focusing on targets with proven biology via novel modalities.

Building on expertise in neurology, the company is initiating a proof-of-concept study in neuromuscular conditions dermatomyositis and polymyositis with enpatoran in 2023.

read more
Merck KGaA Posts Weak FY23 Results; Sees Organic Growth In FY24

Merck KGaA Posts Weak FY23 Results; Sees Organic Growth In FY24

German science and technology major Merck KgaA reported Thursday weak profit and sales in fiscal 2023 amid a challenging market environment. Higher sales in Healthcare business sector were more than offset by weakness in Life Science and Electronics. Looking ahead for fiscal 2024, Merck expects return to organic growth with slight to moderate organic growth in sales and EBITDA pre, with Healthca
RTTNews | il y a 411
Merck KGaA Sees FY23 Results At Lower Half Of Outlook Range, Organic Sales Growth In FY24; Stock Up

Merck KGaA Sees FY23 Results At Lower Half Of Outlook Range, Organic Sales Growth In FY24; Stock Up

German science and technology major Merck KgaA Thursday reconfirmed its earnings and sales forecast for fiscal 2023, but at the lower half of the range after reporting weak profit and sales in its third quarter amid a difficult market environment. Further, the company projects a return to organic sales growth in fiscal 2024. The shares were gaining around 5 percent in the morning trading in German
RTTNews | il y a 530
Merck KgaA Profit Rises, Ups Dividend; Sees Weak To Flat EBITDA Pre In FY23

Merck KgaA Profit Rises, Ups Dividend; Sees Weak To Flat EBITDA Pre In FY23

German science and technology major Merck KgaA reported Thursday higher profit and revenues in its fiscal 2022, with improved performance in all divisions. The company further lifted its dividend, and said it expects weak to flat EBITDA pre in fiscal 2023, but higher organic sales.
RTTNews | il y a 782
CAC 40 Down Marginally

CAC 40 Down Marginally

The French stock market is down marginally on Tuesday as investors, amid lingering concerns over U.S. Government's trade policy and rising tensions between the U.S. and China, largely remain cautious while awaiting some crucial economic data and earnings updates this week.
RTTNews | il y a 16 minutes
DAX Recovers After Early Setback, Down Marginally In Cautious Trade

DAX Recovers After Early Setback, Down Marginally In Cautious Trade

German stocks are down in negative territory on Tuesday, with investors, back to trading after a long Easter break, making cautious moves amid lingering concerns about trade tensions due to the U.S. government's trade policy. The standoff between the U.S. President and the Federal Reserve Chair also appears to be weighing on investor sentiment.
RTTNews | il y a 52 minutes
Walgreens To Pay Up To $350 Mln For Opioid Settlement

Walgreens To Pay Up To $350 Mln For Opioid Settlement

Walgreens Boots Alliance and its units have agreed to pay up to $350 million as it settles with the Justice Department and other federal agencies the allegations of illegally filling unlawful opioid prescriptions and submitting false claims to the Federal Government.
RTTNews | il y a 2h 11min